{"blog": [], "keywords": [{"value": "Crestor (Drug)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "AstraZeneca PLC", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Cholesterol", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Inventions and Patents", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "5", "is_major": "Y"}, {"value": "Children and Childhood", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "7", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/06/28/business/astrazeneca-pushes-to-protect-crestor-from-generic-competition.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK", "contributor": ""}, "type_of_material": "News", "multimedia": [{"url": "images/2016/06/28/business/28CRESTOR/28CRESTOR-thumbWide.jpg", "legacy": {"wide": "images/2016/06/28/business/28CRESTOR/28CRESTOR-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/06/28/business/28CRESTOR/28CRESTOR-articleLarge.jpg", "legacy": {"xlarge": "images/2016/06/28/business/28CRESTOR/28CRESTOR-articleLarge.jpg", "xlargeheight": "396", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 396}, {"url": "images/2016/06/28/business/28CRESTOR/28CRESTOR-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/06/28/business/28CRESTOR/28CRESTOR-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1329", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The drug maker is trying to get its popular anticholesterol pill approved to treat children who have a rare disease characterized by high cholesterol.", "pub_date": "2016-06-28T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "A Fight to Fend Off Generics", "main": "AstraZeneca Pushes to Protect Crestor From Generic Competition"}, "print_page": "1", "snippet": "The drug maker is trying to get its popular anticholesterol pill approved to treat children who have a rare disease characterized by high cholesterol.", "_id": "5771873038f0d82529b0b365", "slideshow_credits": null, "abstract": "Controversy surrounds AstraZeneca's push to extend market exclusivity of its best-selling anti-cholesterol drug Crestor by seeking approval to treat rare condition affecting few hundred American children; company, following unusual legal argument, is arguing that it is entitled to seven years of protection from generic competition under Orphan Drug Act; critics say move abuses law."}